Bodyweight Changes Associated with Antihyperglycaemic Agents in Type 2 Diabetes Mellitus

Author： Hermansen Kjeld Mortensen Lene S.

ISSN： 0114-5916

Source： Drug Safety, Vol.30, Iss.12, 2007-01, pp. : 1127-1142

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy and Tolerability of Pioglitazone in Patients with Type 2 Diabetes Mellitus: Comparison with Other Oral Antihyperglycaemic Agents

By Derosa Giuseppe

Drugs, Vol. 70, Iss. 15, 2010-10 ,pp. : 1945-1961

Adis International

Access to resources Recommend Favorite

The oral antihyperglycaemic agent nateglinide [`Starlix'] has been approved in Switzerland for the treatment of type 2 diabetes mellitus.

Inpharma, Vol. 1, Iss. 1259, 2000-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

Sibutramine improves insulin sensitivity and reduces bodyweight in obese patients with type 2 diabetes mellitus

Inpharma, Vol. 1, Iss. 1507, 2005-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Evaluation of the Potential Clinical and Economic Effects of Bodyweight Stabilisation with Acarbose in Patients with Type 2 Diabetes Mellitus: A Decision-Analytical Approach

By Banz K.

PharmacoEconomics, Vol. 13, Iss. 4, 1998-04 ,pp. : 449-459

Adis International

Access to resources Recommend Favorite

Oral Antidiabetic Agents: Current Role in Type 2 Diabetes Mellitus

By Krentz Andrew J.

Drugs, Vol. 65, Iss. 3, 2005-01 ,pp. : 385-411

Adis International

Access to resources Recommend Favorite